- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Israeli, American Researchers Discover Blood Marker that could Signal Alzheimer’s Diagnosis
The Jerusalem Post reported that a biological blood marker linked to Alzheimer’s disease could eventually serve as a reliable diagnostic blood test for the progressive, fatal dementia has been identified by researchers at Tel Aviv University, Rambam Medical Center/the Techion-Israel Institute of Technology and Harvard University.
The Jerusalem Post reported that a biological blood marker linked to Alzheimer’s disease could eventually serve as a reliable diagnostic blood test for the progressive, fatal dementia has been identified by researchers at Tel Aviv University, Rambam Medical Center/the Techion-Israel Institute of Technology and Harvard University.
According to the article:
Today, diagnosing Alzheimer’s is a long and complicated process, and most doctors use subjective memory tests of cognitive and functional abilities and behavior changes, she said on Tuesday. In special cases, expensive brain scans are carried out that are not yet available in Israel. Sometimes, invasive tests of the brain and spinal fluids are conducted, noted Gozes of the department of human molecular genetics and biochemistry at TAU’s Sackler Faculty of Medicine and of the Sagol School of Neuroscieces.
TAU lead researcher Prof. Illana Gozes commented:
We hope that in the future, it will be possible to use our discovery to develop a simple blood test for this serious disease even in its early stages.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.